Impacts of prior surgical score on the efficacy and safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei
10.3760/cma.j.cn113855-20200224-00117
- VernacularTitle:既往手术评分对肿瘤细胞减灭术加腹腔热灌注化疗治疗腹膜假黏液瘤疗效和安全性影响的研究
- Author:
Xinbao LI
1
;
Yang YU
;
Songlin AN
;
Gang LIU
;
Yanbin ZHANG
;
Zhonghe JI
;
Fengcai YAN
;
Hongbin XU
;
Zheng PENG
;
Yan LI
Author Information
1. 首都医科大学附属北京世纪坛医院腹膜肿瘤外科 100038
- From:
Chinese Journal of General Surgery
2020;35(10):782-787
- CountryChina
- Language:Chinese
-
Abstract:
Objective:s To evaluate the impacts of prior surgical scores(PSS) on the clinical efficacy and perioperative safety of cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) for pseudomyxoma peritonei(PMP).Methods:From the comprehensive PMP database, we collect the cases treated for the first time by CRS+ HIPEC, to form this study cohort. The clinicopathological features, PSS, CRS+ HIPEC details, overall survival(OS), and serious adverse events(SAEs) are systematically analyzed, to study the correlations between PSS and OS or SAEs.Results:335 PMP cases received standardized CRS+ HIPEC in this study. The median OS is 58.2 months for PSS-0 patients, 63.7 months for PSS-1, and 55.4 months for PSS-2/3, with no statistically significant differences in OS among the different PSS groups(χ 2=0.499, P=0.779). Subgroup analysis by pathologic types also found no statistically significant differences among the different PSS groups. Moreover, no significantly statistical differences are observed in overall SAEs(χ 2=0.625, P=0.722), CRS-related SAEs(χ 2=0.267, P=0.901), and non-CRS-related SAEs(χ 2=0.677, P=0.715), among the different PSS groups. Conclusions:PSS does not pose significant impacts on the efficacy and safety of CRS+ HIPEC for PMP patients at experienced treatment center.
